Intercept Pharmaceuticals Inc.
Intercept Pharmaceuticals Inc. is listed today as Intercept Pharmaceuticals: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2012 | $30 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Intercept Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2012).
SEC Form D · Sep 2012
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2012
That is all the official record says: Intercept Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Intercept Pharmaceuticals Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| OrbiMed Capital GP IV LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| S.p.A. Genextra | Person | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 2 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Barbara E. Duncan | Executive officer | Sep 2012 |
| David E. Shapiro | Executive officer | Sep 2012 |
| Luciano E. Adorini | Executive officer | Sep 2012 |
| Mark E. Pruzanski | Executive officer | Sep 2012 |
| Jonathan T. Silverstein | Director | Sep 2012 |
| Klaus T. Veltinger | Director | Sep 2012 |
| Lorenzo E. Tallarigo | Director | Sep 2012 |
| Mark E. Pruzanski | Director | Sep 2012 |
| Nicole E. Williams | Director | Sep 2012 |
| Paolo E. Fundaro | Director | Sep 2012 |
| Klaus T. Veitinger | Director | Aug 2012 |
About
American biopharmaceutical company.